Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Announces Closing of Share Exchange and Asset Purchase (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(33)
•••
Comment by toinv261on Jun 11, 2014 3:05pm
167 Views
Post# 22650470

RE:RE:RE:RE:RE:RE:RE:DIRECTORS AND OFFICERS OF RVX PARTICIPATE IN PRIVATE PLACEME

RE:RE:RE:RE:RE:RE:RE:DIRECTORS AND OFFICERS OF RVX PARTICIPATE IN PRIVATE PLACEMEHi Sanfran.

Yes, you got it...insiders finally putting up their own money to get more shares. They must be looking for the payback and that hints of the following. It suggests...
  1. That the insiders, those that know all of the research over the years and the current post hoc analysis of the combined trial analysis feel very strongly about the future of rvx-208.
  2. That insiders may know something about the diabetes trial results.
  3. That Dr Peter Johann, Chair of the Board of RVX, believes strongly enough in rvx-208 that he is bringing in NGN to give more support to RVX. He, potentially, benefits from both companies.
  4. That something big may happen soon.
  5. That Don is negotiating hard and not giving in to a low ball hit from other suitors.

IMO of course. One thing for sure, this thing is big and not fading away any time soon.

In a communications vacuum I'm guessing that there may be some barriers to trial negotiations such as the structural relationship between Zenith and RVX and then the obvious structural development of the CVR.

Cheers
Toinv


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities